ILAR’s advisory body, the ILAR Council, serves four principal functions:
- to provide program direction and strategic planning;
- to oversee information and communication programs (e.g., the ILAR website and the quarterly ILAR Journal);
- to oversee studies, reports, workshops, and other projects; and
- to direct ILAR’s international programs.
The ILAR Council meets for two days twice annually.
Margaret S. Landi, Chair
Chief of Animal Welfare, Ethics and Strategy
Novartis International AG
Associate Professor of Molecular and Comparative Pathobiology
Johns Hopkins University
Joseph J. DeGeorge
Global Head of Safety Assessment and Laboratory Animal Resources
Merck Research Laboratories
Scientific Director, Head of Toxicology and Laboratory Animal Medicine
Johnson and Johnson, Janssen Pharmaceuticals
Lewis B. Kinter
Paul A. Locke
Associate Professor, Department of Environmental Health and Engineering
Director, DrPH Program in Environmental Health Sciences
Johns Hopkins Bloomberg School of Public Health
Daniel S. Marsman
Head, Safety and Regulatory Affairs
Procter and Gamble Health Care
Melinda A. Novak
Professor of Psychology
University of Massachusetts
James A. Roth
Clarence Hartley Covault Distinguished Professor
Director, Center for Food Security and Public Health
College of Veterinary Medicine
Iowa State University
Lawrence B. Schook
Vice President for Research
Edward William and Jane Marr Gutgsell Professor
University of Illinois
Robert S. Sikes
Professor of Biology
University of Arkansas at Little Rock
Dr. Margaret S. Landi is Chief of Animal Welfare, Ethics and Strategy for GlaxoSmithKline. Her role is to provide leadership, guidance, set policies and guidance as Chief Veterinarian for GSK. As Risk Owner for Animals she is responsible to ensure that the quality of animal work is independent of location of study conductance, there is compliance with Corporate Policy 403 and consistency in practices associated with all aspects of the animal care and use programs at GSK sites. Margaret is a Diplomate in the American College of Laboratory Animal Medicine (ACLAM) and Past- President of the organization. Presently she is the Chairperson of the Council of the Institute of Laboratory Animal Research (ILAR), a part of the National Academy of Science in the US. Margaret has served on review committees of the National Institutes of Health (NIH), has led special site visit teams for NIH Committees and am a past ad-hoc member of AAALAC. She has a VMD from the University of Pennsylvania, at Masters in Comparative Medicine from the Penn State University and is targeted to complete her Masters in Bioethics from the University of Pennsylvania in 2017. Recent areas of presentations and publications are in the application of global principles for laboratory animals in an international arena with differing laws, cultures, regulations and policies.
Dr. Karin Blumer is a German veterinarian and philosopher, Director of ScienceCommunication and Policy at Novartis International company, located in Basel, Switzerland. After completion of academic studies at the Ludwig-Maximilians-University Munich and the Jesuit Faculty for Philosophy/Munich, she worked as freelance science journalist and policy advisor. In 2001, she joined Novartis International in Basel where she held a variety of different positions in R&D policy, public affairs and science communication. Her professional areas of expertise include digital health, the responsible use of health data, bioethics, animal research, strategic science communication, corporate governance and compliance. She is a member of the European industry’s task force on animal research policies at EFPIA, the European Federation of Pharmaceutical Industries and Associations and co-chair of the Ethics Advisory Board (EAB) of the Human Brain Project, a European Commission Future and Emerging Technologies Flagship project. Karin Blumer authored two interdisciplinary doctorate treatises on the ethics of animal research and the philosophy of risk. She lectures at the University Basel on bioethical issues.
Dr. Cory Brayton is Associate Professor, and Director of Phenotyping and Pathology Core Facility at Johns Hopkins University, School of Medicine. She is a diplomate of the American College of Laboratory Animal Medicine (ACLAM), and of the American College of Veterinary Pathologists (ACVP). She served as president of ACVP in 2014, as well as on ACVP Council 2009-2012, and as president elect, 2013. She received her DVM from Cornell University, and did postdoctoral research and pathology training in New York City at the Animal Medical Center, Cornell University and The Rockefeller University. At The Rockefeller University (1989-1992), she became specifically interested in the pathology and characterization (phenotyping) of genetically engineered mice (GEM), and continued to pursue this interest at several institutions while heading the Facility for Comparative Studies at the Hospital for Special Surgery (1992-1998). At Baylor College of Medicine (1998-2004), she headed the Comparative Pathology Laboratory, and was responsible for health surveillance and diagnostic pathology for a diverse research population including more than 150,000 mice. She also was associate professor in pathology, associate director of the Center for Comparative Medicine, interim attending veterinarian, and served on the IACUC, while pursuing research collaborations, teaching initiatives, and developing national and international conferences on the characterization and pathology of genetically engineered mice. In 2004 she moved to John Hopkins to develop a collaborative phenotyping core based in the Department of Molecular and Comparative Pathobiology (MCP), where veterinarian postdoctoral trainees and faculty investigators provide a unique comparative and translational research resource, in an institution with exceptional resources for multidisciplinary biomedical research. She has been on ILAR council, and CoEIC of ILAR journal since 2012.
Dr. Joseph J. DeGeorge is Vice President of Global Safety Assessment and Laboratory Animal Resources with responsibility for non-clinical safety testing. He has served on or chaired committees on drug discovery, drug candidate selection, early and late development, and post marketing safety. In addition to his position with Merck, he also serves as the PhRMA Clinical and Preclinical Development Committee co-chair and as Coordinator for ICH Safety Topics. He has participated in the development of numerous ICH Safety Guidance’s as a chair or member of Safety and Multidisciplinary ICH Expert Working Groups. Before working at Merck, he served as Vice President of Preclinical Safety Evaluation at Novartis Pharmaceuticals and as the Global Chair for the Research and Development Safety Assessment Committee, with responsibility for first in human studies. Prior to Novartis, he worked at the Food and Drug Administration (FDA), where he was last the Associate Director for Pharmacology and Toxicology in the Center for Drug Evaluation and Research (CDER). Prior to joining FDA, Dr. DeGeorge was a Senior Staff Fellow at the National Institutes of Health, National Institute on Aging, Laboratory of Neurosciences, where he worked on development of in vivo functional and structural brain imaging probes. He completed his postdoctoral training as a Fellow at the University of North Carolina, Chapel Hill, with a joint appointment at Burroughs Wellcome Research Institute, Research Triangle Park, NC, where he focused on neural cell to cell signaling and second messenger systems. Dr. DeGeorge received his Ph.D. in Pharmacology from the State University of New York/Upstate Medical Center.
Dr. Michael DuVall joined Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson in 2012 and is currently a Scientific Director and the US Head Toxicology and Laboratory Animal Medicine. Before joining Johnson & Johnson, Dr. DuVall was an Associate Director and Toxicology Project Lead in Preclinical Safety Evaluation at Abbott Laboratories and a Toxicology Study Director at Covance Laboratories. Michael received his DVM from Texas A&M University (1988) and his PhD from the College of Veterinary Medicine at the University of Minnesota (1993). He completed his post-doctoral training in the Cystic Fibrosis Center and Department of Anesthesiology at the University of Alabama at Birmingham where he studied the effects of reactive oxygen and nitrogen species on epithelial chloride and sodium channel protein function. Throughout his professional career, Michael has been a strong advocate of the ethical use of animals in research and has been active on multiple IACUCs. He is currently the Chairman of the Johnson & Johnson Animal Care and Use Council.
Dr. Lewis B. Kinter is currently President and Principal Scientist at GLP Scientific Consulting, Unionville, PA, USA. He has been engaged in pharmaceutical, biological, and medical device research and development for over 30 years and is an internationally recognized expert in nonclinical R&D. Dr. Kinter received his BS in Biology at Union College (1973) and his doctorate in Medical Physiology from Harvard University (1978). From 1981 to 2014 he held positions of increasing responsibility in biomedical R&D with Smith Kline & French, SmithKline Beecham, Sterling Winthrop, Nycomed Amersham, Astra Merck, and AstraZeneca. Dr. Kinter is a Diplomate of the American Board of Toxicology, Fellow of the Academy of Toxicological Sciences, Professor of Pharmacology & Toxicology (Adjunct) Michigan State University, and has authored over 100 research manuscripts and book chapters in basic and applied physiology, pharmacology, and toxicology. Dr. Kinter serves in leadership capacities on several Boards of professional scientific and charitable organizations.
Dr. Paul A. Locke, an environmental health scientist and attorney, is an Associate Professor at the Johns Hopkins Bloomberg School of Public Health in the Department of Environmental Health and Engineering. He holds a joint appointment in the Department of Health Policy and Management. Dr. Locke has an MPH from Yale University School of Medicine, a DrPH from the Johns Hopkins University Bloomberg School of Public Health and a JD degree from Vanderbilt University School of Law. At Hopkins, Dr. Locke leads an integrated research, practice and teaching program. His program focuses on research-to-practice initiatives to better protect public health, especially in advancing evidence-based in vitro toxicology and radiation protection policy at federal and international organizations. He has published widely in both law reviews and scientific and policy journals, and has developed three cross-disciplinary courses in environmental law and policy and animal law. Dr. Locke also directs the School’s Doctor of Public Health program in Environmental Health Sciences and a certificate program in Humane Sciences and Toxicology Policy. Dr. Locke is admitted to practice law in the state of New York and the District of Columbia, the Southern District Court of New York and is a member of the bar of the United States Supreme Court. He is also a member of the Science Board of the American Public Health Association (APHA). He is the recipient of the Yale School of Public Health Alumni Service Award and the American Public Health Association Environment Section Distinguished Service Award.
Dr. Daniel S. Marsman leads and manages the Product Safety division for Procter & Gamble’s worldwide Health Care business, and serves as corporate veterinarian and a technical external lead for P&G’s Animal Alternatives and Animal Welfare programs. His interdisciplinary career has embraced the concept of ‘One Health, One Medicine’, beginning with his veterinary training (Michigan State University), WHO medical parasitology research in sub-Saharan Africa, his PhD in pathology from the College of Human Medicine, UNC-Chapel Hill, and his postdoctoral fellowship studying the pathobiology of neoplasia at CIIT/Hamner Institute, Research Triangle Park, NC. He has previously served as pathologist/study scientist for the NIH’s National Institute of Environmental Health Sciences, and as Head of Study Design for the NTP chronic toxicity/carcinogenicity testing program. Dr. Marsman’s previous positions at P&G have included toxicological pathologist in the Human Safety department, research scientist in the carcinogenesis group, and global safety/regulatory affairs manager for Household, Baby, Feminine, Family and Pet Care. He has published and consulted extensively in the fields of toxicology, pathology, animal welfare and animal alternatives. His collaborative contributions have spanned governmental, NGO and trade association technical and policy committees, including past Chair of the Animal Welfare Committee of the AVMA, current charter diplomate in AVMA’s American College of Animal Welfare.
Dr. Melinda Novak is Professor in the Department of Psychological and Brain Sciences at the University of Massachusetts - Amherst. She received her Ph.D. from the University of Wisconsin and accepted a faculty position at the University of Massachusetts where she established the UMass Primate Laboratory, a small primate facility in which students receive training in handling and managing captive primates, performing behavioral and health assessments, and conducting research. She is currently the Director of this facility. Her federally funded research links four Primate Research Centers and is focused on the causes of and treatment for abnormal behavior in primates using a cross translational model wherein monkey research informs human research and vice-versa. Dr. Novak is a past President of the American Society of Primatologists and is a recent recipient of the Distinguished Primatologist Award from this society. Dr. Novak was a member of two National Academy of Sciences’ Committees, one on Psychological Well-being of Nonhuman Primates and the other on Recognition and Alleviation of Distress in Laboratory Animals. Dr. Novak has served on the Board of Trustees of AAALAC International, the Scientific Advisory Committee of SCAW (Scientists’ Center for Animal Welfare), and has also served on a number of other advisory boards, journal editorial boards, and federal grant review panels. She was a reviewer of the updated NIH Guide to the Care and Use of Laboratory Animals. She is a current member of the Scientific Advisory Committee for the Wisconsin National Primate Center in Madison. Dr. Novak regularly reviews primate facilities and provides advice and guidance on psychological well-being programs. At the University level, Dr Novak is a past recipient of the College Outstanding Teacher Award, The Distinguished Faculty UMass Alumni Association Award, The Award for Outstanding Accomplishments for Research and Creative Activity, an Exceptional Merit Award, the Conti Research Faculty Fellowship Award, and the Chancellor’s Medal for Distinguished Faculty Lecturer, the highest honor bestowed on faculty for exemplary research and service contributions.
Dr. James Roth is a Clarence Hartley Covault Distinguished Professor in the Department of Veterinary Microbiology and Preventative Medicine in the College of Veterinary Medicine at Iowa State University. He received DVM (1975) and PhD (1981) degrees from ISU. He is the Director of the Center for Food Security and Public Health, an OIE Collaborating Center for Day One Veterinary Competencies and Continuing Education, and the Institute for International Cooperation in Animal Biologics, an OIE Collaborating Center for Diagnosis of Animal Disease and Vaccine Evaluation in the Americas. Dr. Roth's primary area of research expertise is immunity to infectious diseases of food-producing animals. Dr. Roth received the Distinguished Veterinary Microbiologist Award from the American College of Veterinary Microbiologists, The Distinguished Veterinary Immunologist Award from the American Association of Veterinary Immunologists, the Public Service Award from the American Veterinary Medical Association and the USDA APHIS Administrator's Award for lifetime achievements in animal health. He has testified before Congress on biosecurity preparedness and efforts to address bioterrorism and agroterrorism. Dr. Roth served on the National Science Advisory Board for Biosecurity from its inception in 2005 until 2014. He was elected to the National Academy of Medicine in 2016.
Dr. Lawrence B. Schook is an Edward William and Jane Marr Gutsgell Professor of Animal Sciences and Radiology and previously served as the Vice President for Research at the University of Illinois, overseeing the technology commercialization and economic development activities across the University’s three campuses (Urbana-Champaign, Chicago, Springfield). Schook is a recognized international scholar in comparative genomics and is known for leading the pig genome-sequencing project, which has provided researchers insights into human cancer and other chronic diseases. He is a noted entrepreneur who has launched two medical application startup companies and is a Fellow at the Academy for Entrepreneurial Leadership. He has served as an advisor to corporations, universities, and government agencies with respect to medical models, genomics, and animal biotechnology. Schook led the effort to develop UI LABS, a Chicago-based research and commercialization collaborative that spun out of the University, and is a founding Board member. He currently serves on the Boards of Trustees for Albion College, the National Academy of Sciences Institute for Laboratory Animal Science Council, the Current Water Innovation Cluster Board, and the Illinois Technology Association Internet of Things Council. He is a member of the Joint Center for Energy Storage Research (JCESR) Governance Board and co-chairs the Chicago Metro Metals Consortium’s Research & Innovation Subcommittee and the Illinois Manufacturing Laboratory Executive Committee. He previously served on the Board of Managers for the Fermi and Argonne National Laboratories, Illinois Governor Quinn’s Innovation Council, the Biotechnology Industry Organization (BIO) Board of Directors, the BIO Governing Board on Food and Agriculture, the Agricultural Biotechnology International Conference Foundation, and the boards of multiple biotechnology companies. He served as Chair for the International Swine Genome Sequencing Consortium, a pig genome sequencing collaboration among global academic, government, and industry representatives. Schook attended Albion College (BA, 1972; Distinguished Alumni Award, 1996) and received his MS and PhD from Wayne State University School of Medicine. He is an elected Fellow of the American Association for the Advancement of Science and was a Fulbright Distinguished Chair in genomics at the University of Salzburg. He has mentored 75 students and 20 postdoctoral fellows, has written more than 250 published works, has edited six books, and is founding editor of Animal Biotechnology.
Dr. Robert Sikes’s academic training and research interests center on the behavioral and evolutionary ecology of mammals. With regard to oversight of animal use, Dr. Sikes served both as IACUC member and as chair prior to assuming his current roles as Professor of Biology and Director of the Basic Animal Services Unit of the University of Arkansas at Little Rock. Dr. Sikes has been a member of the Animal Care and Use Committee of the American Society of Mammalogists since 1997 and has chaired that committee since 2008. He has been a panelist at various symposia on the use of wild animals in research and was co-convenor of the 2011 conference on IACUC oversight of wildlife research in Albuquerque, NM. He regularly presents at national meetings on topics related to the oversight of wildlife research. Dr. Sikes is senior author of the current (2011) Guidelines of the American Society of Mammalogists for the use of Wild Mammals in Research.